PMID- 36654959
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230120
IS  - 2227-684X (Print)
IS  - 2227-8575 (Electronic)
IS  - 2227-684X (Linking)
VI  - 11
IP  - 12
DP  - 2022 Dec
TI  - Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on 
      pathological complete response to neoadjuvant pertuzumab and trastuzumab 
      treatment-a retrospective cohort study.
PG  - 1887-1896
LID - 10.21037/gs-22-632 [doi]
AB  - BACKGROUND: Human epidermal growth factor receptor-2 (HER-2) protein expression 
      level could serve as a predictor of pathological complete response (pCR) to 
      neoadjuvant trastuzumab-containing regimens. The aim of the present study was to 
      evaluate whether pCR to neoadjuvant trastuzumab and pertuzumab treatment is 
      dependent on the level of the HER-2/CEP17 (chromosome enumeration probe 17) ratio 
      in immunohistochemistry (IHC) 2+/fluorescence in situ hybridization 
      (FISH)-amplified breast cancer. METHODS: Patients with primary IHC 
      2+/FISH-amplified breast cancer who underwent neoadjuvant anti-HER-2 
      dual-targeted therapies were retrospectively included between January 1, 2020 and 
      May 30, 2021. The primary predictive variable was HER-2/CEP17 ratio, and the 
      primary outcome variable was pCR. Other variables consisted of age, menopausal 
      status, tumor-node-metastasis (TNM) stage, estrogen receptor (ER), progesterone 
      receptor (PgR), and Ki-67. Association between clinicopathologic variables and 
      pCR was evaluated using the chi-square test and logistic regression analysis. 
      RESULTS: The median age of the patients was 51.78 years (25-67 years), and 50.7% 
      of the patients were in the premenopausal stage. The clinical stage at diagnosis 
      was Stage III in 38 patients (55.1%). Of all patients, 40.6% patients were 
      estrogen receptor positive, and 75.4% patients had a Ki-67 index of >/=30%. The 
      overall pCR (ypN0/isypN0) rate was 31.9%. Patients with HER-2/CEP17 ratio >/=6.0 
      had a pCR rate of 55.0%, it was statistically higher than 22.4% in patients with 
      HER-2/CEP17 ratio <6.0. Logistic regression analysis confirmed the independent 
      association between HER-2/CEP17 ratio and pCR (P=0.020, OR: 5.203, 95% CI: 
      1.302-20.783). CONCLUSIONS: A HER-2/CEP17 ratio >/=6.0 might be related to more 
      achievement of pCR in the neoadjuvant anti-HER-2 dual-targeted therapies. Further 
      studies are needed to validate the finding.
CI  - 2022 Gland Surgery. All rights reserved.
FAU - Wang, Jiabin
AU  - Wang J
AD  - Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China.
FAU - Qiao, Jianghua
AU  - Qiao J
AD  - Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China.
FAU - Ruan, Yuxia
AU  - Ruan Y
AD  - Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China.
FAU - Wang, Chengzheng
AU  - Wang C
AD  - Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China.
FAU - Li, Lianfang
AU  - Li L
AD  - Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China.
FAU - Lu, Zhenduo
AU  - Lu Z
AD  - Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China.
FAU - Sun, Xianfu
AU  - Sun X
AD  - Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China.
FAU - Zhang, Chongjian
AU  - Zhang C
AD  - Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China.
FAU - Chen, Xiuchun
AU  - Chen X
AD  - Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China.
FAU - Yan, Min
AU  - Yan M
AD  - Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China.
FAU - Cui, Shude
AU  - Cui S
AD  - Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China.
FAU - Liu, Zhenzhen
AU  - Liu Z
AD  - Department of Breast Disease, The Affiliated Cancer Hospital of Zhengzhou 
      University & Henan Cancer Hospital, Zhengzhou, China.
LA  - eng
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Gland Surg
JT  - Gland surgery
JID - 101606638
PMC - PMC9840990
OTO - NOTNLM
OT  - HER2-positive breast cancer
OT  - neoadjuvant chemotherapy (NAC)
OT  - pathological complete response (pCR)
OT  - pertuzumab
OT  - trastuzumab
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://gs.amegroups.com/article/view/10.21037/gs-22-632/coif). The authors have 
      no conflicts of interest to declare.
EDAT- 2023/01/20 06:00
MHDA- 2023/01/20 06:01
PMCR- 2022/12/01
CRDT- 2023/01/19 01:59
PHST- 2022/09/20 00:00 [received]
PHST- 2022/12/16 00:00 [accepted]
PHST- 2023/01/19 01:59 [entrez]
PHST- 2023/01/20 06:00 [pubmed]
PHST- 2023/01/20 06:01 [medline]
PHST- 2022/12/01 00:00 [pmc-release]
AID - gs-11-12-1887 [pii]
AID - 10.21037/gs-22-632 [doi]
PST - ppublish
SO  - Gland Surg. 2022 Dec;11(12):1887-1896. doi: 10.21037/gs-22-632.